Emcor Group Inc

NYSE: EME
$526.95
+$11.13 (+2.2%)
Closing Price on November 21, 2024

EME Stock Chart and Intraday Price

EME Stock Data

Asset Type Stock
Exchange NYSE
Currency USD
Country USA
Sector REAL ESTATE & CONSTRUCTION
Industry ELECTRICAL WORK
Address 301 MERRITT SEVEN CORPORATE PK, 6TH FLOOR, NORWALK, CT, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 15,060.30M USD
Shares Outstanding 47,064,900
Emcor Group Inc is a leading provider of construction, building, and industrial services across the United States and the United Kingdom. Specializing in a wide array of services, Emcor offers everything from electrical and lighting systems, energy solutions, and HVAC services to fire protection, plumbing, and water treatment systems. The company extends its expertise to include comprehensive building services such as facility management, energy efficiency retrofits, and janitorial services. Additionally, Emcor is involved in refinery turnaround, welding, and renewable energy services, showcasing its diverse capabilities in supporting infrastructure and building projects. Founded in 1987, Emcor is headquartered in Norwalk, Connecticut.

EME Articles

Tuesday's top analyst upgrades and downgrades included Advanced Micro Devices, Block, Bumble, DigitalOcean, Duke Realty, FirstEnergy, HF Sinclair, Nio, Petco Health and Wellness, Roblox, Rocket...
The top analyst upgrades, downgrades and initiations seen on Friday included Activision Blizzard, BioMarin Pharmaceuticals, Ciena, Delta Air Lines, GlaxoSmithKline, Procter & Gamble, Regeneron...
More than half of the American workforce is comprised of women. It is well-known that they are paid less than their male counterparts. Several studies show that female workers make about 77%  of the...
Women make up over 50% of the US workforce now, but the Bureau of the Census shows that women make, on average, only 77% of what men do based on measurements of annual salaries. 24/7 Wall St. looked...
(ADLR) Adolor said a complete response to the POI ‘Approvable’ Letter now targeted for 3Q 2007.(ALXN) Alexion Pharm says studies show efficacy and safety of it’s Soliris in broad population of...